Latest From Biocon Ltd.
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
Endo has named a head for its sterile injectables and generics operations; Hikma has appointed an R&D head; Acino has a new leader for its Latin American business; Alvogen has appointed a general counsel; and Julphar has shaken up its senior management team.
Mylan-Biocon’s biosimilar Herceptin debuts in Australia, promising to provide patients a high quality and affordable alternative, though at least three competing trastuzumab versions including Amgen’s Kanjinti are in the wings.
- Large Molecule
- Medical Devices
- Therapeutic Areas
- Parent & Subsidiaries
- Biocon Ltd.
- Senior Management
Arun Chandavarkar, PhD, CEO
Siddharth Mittal, CFO
Ravi Limaye, Pres., Mktg.
Narendra Chirmule, PhD, SVP & Head, R&D
- Contact Info
Phone: (91) 80 2808 2808
20th KM Hosur Rd.
Bangalore , 560 100
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.